Based on the FDA’s written comments, United Therapeutics Corporation (NASDAQ: UTHR) has decided to discontinue the development of Trevyent.
- Trevyent is a drug-device combination product that combines two-day, single-use, disposable PatchPump technology with treprostinil for the subcutaneous treatment of pulmonary arterial hypertension.
- The comments followed a meeting to discuss the company’s planned resubmission of its marketing application for Trevyent in light of a Complete Response Letter issued in April last year.
- The FDA’s comments indicated that United Therapeutics would need to redesign the product to improve pump accuracy in certain respects and conduct a clinical study of the redesigned product.
- Thus, the company will stop the development of Trevyent as it is no longer considered commercially reasonable.
- Initially, the company submitted Trevyent application in September 2019.
- The company expects to incur an impairment charge of roughly $107.3 million during the first quarter of 2021.
- Price Action: UTHR shares are down 0.35% at $166 in premarket trading on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in